Back to Search
Start Over
Efficacy and tolerability of oxcarbazepine in the treatment of focal epilepsy in neonates and infants under 3 months of age: A single-center retrospective analysis.
- Source :
-
Epilepsy Research . Nov2023, Vol. 197, pN.PAG-N.PAG. 1p. - Publication Year :
- 2023
-
Abstract
- The neonatal and infantile period is the age group with the highest incidence of epilepsy, in which gene variants in sodium and potassium channels are an important etiology, so the sodium channel blocker class of antiseizure medications may be effective in the treatment of early onset epilepsy. This study aimed to summarize the efficacy and tolerability of oxcarbazepine (OXC) in the treatment of focal epilepsy in neonates and infants under 3 months of age. A retrospective analysis of children with focal epilepsy onset within 3 months of age and treated with OXC in a tertiary pediatric epilepsy center in China was conducted. The efficacy, tolerability and influencing factors of OXC were evaluated. A total of 50 patients were enrolled, with a median age of epilepsy onset of 11.5 (2, 42) days. There were 32 cases of early infantile developmental and epileptic encephalopathy, 10 cases of self-limited neonatal or neonatal-infantile epilepsy, and 8 cases of focal epilepsy that could not be classified as epileptic syndrome. The median age of application of OXC was 47 (31, 66) days. The median follow-up time was 16.5 (10, 25) months, with 7 deaths. Thirty-eight cases (76.0 %) were effective with OXC treatment, including 28 cases (56.0 %) achieved seizure freedom. Of the 34 cases whose pathogenesis involved genetic factors, 19 cases with sodium/ potassium channel gene variants had higher effective and seizure-free rates than those with other gene variants. The most common adverse event was transient hyponatremia. 2 cases had rash and 2 cases had abnormal electrocardiogram, 3 of which discontinued OXC. This single-center retrospective study suggests that OXC is effective and tolerable for the treatment of focal epilepsy in neonates and infants under 3 months of age. The efficacy of OXC is better in patients with sodium/ potassium channel gene variants. • Oxcarbazepine is effective and tolerable in the treatment of focal epilepsy in neonates and very young infants. • Oxcarbazepine is with higher efficiency in patients with GOF variants of sodium channel genes and LOF variants of potassium channel genes. • Adverse reactions leading to withdrawal of oxcarbazepine are skin rashes and premature ventricular rhythm. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 09201211
- Volume :
- 197
- Database :
- Academic Search Index
- Journal :
- Epilepsy Research
- Publication Type :
- Academic Journal
- Accession number :
- 173315456
- Full Text :
- https://doi.org/10.1016/j.eplepsyres.2023.107240